AUTHOR=Ma Yu-Ting , Li Yan , Yan Li , Hua Fang , Wang Dong-Guan , Xu Guo-Ying , Yang Hong-Lan , Xue Ying-Jie , Qin Ye-Jun , Sha Dan , Ning Hao , Zhao Miao-Qing , Yao Zhi-Gang 

TITLE=Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma

JOURNAL=Pathology and Oncology Research

VOLUME=Volume 28 - 2022

YEAR=2022

URL=https://www.por-journal.com/journals/pathology-and-oncology-research/articles/10.3389/pore.2022.1610638

DOI=10.3389/pore.2022.1610638

ISSN=1532-2807

ABSTRACT=Immune checkpoint inhibitors (ICIs) have shown encouraging outcomes against Lynch syndrome (LS)-associated colorectal cancer (CRC) and endometrial cancer with mismatch repair deficient/microsatellite instability high (dMMR/MSI-H). However, the safety and efficacy of immunotherapy combined with chemotherapy in LS-associated urothelial carcinoma (UC) is unclear. Here, we report a patient with recurrent and metastatic LS-associated UC, who achieved sustained response to programmed death 1 (PD-1) inhibitor sintilimab combined with chemotherapy over 31 months, during which the side effects of immunotherapy could be controlled and managed. Our findings indicate dMMR/MSI status and PD-1 expression on UC may have potential predictive value for response to PD-1-targeted immunotherapy. Our case supports the inclusion of such combination and/or monotherapy for UC in clinical studies and using dMMR/MSI status and PD-1 expression as potential predictive biomarkers for assessment of therapeutic response.